(BFW) Gates Wants Saint-Gobain to Be Required to Bid for All of Sika



Gates Wants Saint-Gobain to Be Required to Bid for All of Sika
2015-03-06 18:52:36.428 GMT


By Jim Silver
(Bloomberg) -- Bill & Melinda Gates Foundation, Cascade
Investment, which jointly own 3% of Sika, ask Swiss Takeover
Board to oblige Saint-Gobain to bid for all shrs, Sika says in
statement.
* NOTE: Earlier, Swiss Takeover Board Takes Decision on Sika
Opting-Out
* NOTE: Jan. 22, Gates, Fidelity Launch Counter-Offensive
Against Sika Takeover

For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>

To contact the reporter on this story:
Jim Silver in New York at +1-212-617-7342 or
jsilver@bloomberg.net
To contact the editors responsible for this story:
Andrea Snyder at +1-202-624-1831 or
asnyder5@bloomberg.net
James Kraus

>>> US Close Dow+0,21% S&P+0,12% Nasdaq+0,31% Russell+0,29%

Closing Market Summary: Stocks Inch Higher as Dollar Index Extends 2015 Gain

The stock market ended the Thursday session on a modestly higher note with the Nasdaq Composite (+0.3%) settling in the lead. The tech-heavy index is now up 0.4% week-to-date, while the S&P 500 (+0.1%) will enter the Friday session lower by 0.2% for the week.

In a way, today's session fit right in with recent affairs as equity indices maintained narrow ranges amid light volume. The S&P 500 spent the day inside a nine-point range while NYSE floor volume totaled fewer than 675 million shares (50-day average 766 million).

Six of ten sectors registered gains with three of four countercyclical groups ending ahead of the broader market. To that point, consumer staples (+0.3%), health care (+0.4%), and utilities (+0.8%) spent the day ahead of the broader market while telecom services (-0.1%) lagged.

Most notably, the health care sector was underpinned by biotechnology after AbbVie (ABBV 56.85, -3.42) agreed to acquire Pharmacyclics (PCYC 254.22, +23.74) for $261.25/share. Shares of PCYC jumped 10.3% while the broader iShares Nasdaq Biotechnology ETF (IBB 347.67, +7.58) advanced 2.2%, helping the Nasdaq finish in the lead.

However, the relative strength among biotech names masked a significant soft spot in the market. Specifically, the largest stock by weight—Apple (AAPL 126.39, -2.15)—lost 1.7%, which prevented equity indices from revisiting their morning highs. Meanwhile, the technology sector (-0.1%) held up relatively well despite Apple's weakness. Large cap names like IBM (IBM 161.18, +1.76) and Google (GOOGL 581.44, +3.10) gained 1.1% and 0.5%, respectively, while chipmakers also displayed relative strength with the PHLX Semiconductor Index adding 0.1%.

Similar to technology, growth-sensitive energy (-0.6%) and materials (-0.4%) settled in the red while the other cyclical sectors registered gains.

The energy sector finished at the bottom of today's leaderboard with crude oil contributing to the weakness. The energy component fell 1.5% to $50.76/bbl as dollar strength sent the Dollar Index (96.37, +0.40) to a fresh high for the year. The greenback rallied against the euro, dropping the euro/dollar pair to 1.1030 after European Central Bank President Mario Draghi said the central bank will begin its QE program on March 9, buying negative-yielding bonds up to the deposit rate, which is currently at -0.2%.

On the flip side, the financial sector (+0.4%) ended among the leaders ahead of the 16:30 ET release of the Fed's stress test. The Federal Reserve will announce capital levels of 31 major banks this evening while next Wednesday evening will feature the release of complete results. Bank of America (BAC 16.00, +0.16) led the majors with a 1.0% gain.

Treasuries spent some time on either side of their flat lines before ending with slim gains, sending the 10-yr yield lower by a basis point to 2.11%.

Economic data included jobless claims, productivity/labor cost data, and factory orders:
  • The initial claims level increased to 320,000 from an unrevised 313,000 while the consensus expected a decline to 295,000 
    • The reading marked the highest level of initial claims since May 2014 when it reached 327,000 
    • The Department of Labor reported that no special factors impacted this week's claims reading 
    • The continuing claims level increased to 2.421 million from an upwardly revised 2.404 million (from 2.401 million) 
  • Nonfarm business productivity for Q4 2014 was revised down to -2.2% from an originally reported -1.8% while the consensus expected a revision down to -2.3%
    • Annual productivity in 2014 was 0.7%, which was the smallest annual gain since increasing only 0.2% in 2011 
    • Unit labor costs were revised up to 4.1% from 2.7% while the consensus expected a revision up to 2.9% 
  • Factory orders declined 0.2% in January after declining 3.5% in December while the consensus expected an increase of 0.6% 
    • Almost the entire decline can be attributed to low oil prices as petroleum refinery orders declined 11.6% in January after declining 15.8% in December. Excluding petroleum, factory orders increased a solid 1.1% in January 
Tomorrow, the Nonfarm Payrolls report for February (consensus 240K) and the January Trade Balance (consensus -$42.00 billion) will be released at 8:30 ET while the Consumer Credit report for January (expected $14.00 billion) will cross the wires at 15:00 ET.
  • Nasdaq Composite +5.2% YTD 
  • Russell 2000 +2.5% YTD 
  • S&P 500 +2.1% YTD 
  • Dow Jones Industrial Average +1.8% YTD

RTR UNICREDIT, INTESA, KKR TO LAUNCH RESTRUCTURED LOAN PROJECT IN COMING WEEKS

UNICREDIT, INTESA, KKR TO LAUNCH RESTRUCTURED LOAN PROJECT IN COMING WEEKS - SOURCES
UniCredit, Intesa, KKR to launch loan vehicle in weeks - sources CRDI.MI ISP.MI KKR.N - RTRS

MILAN, March 5 (Reuters) - Italy's top two banks, Intesa Sanpaolo ISP.MI and UniCredit CRDI.MI, will launch a plan to pool some of their restructured loans with the help of U.S. private equity fund KKR KKR.N in the coming weeks, three sources close to the matter said.

Italian lenders had bad debts worth around 330 billion euros ($364 billion) at the end of June as a result of a three-year-long recession.

Intesa Sanpaolo and UniCredit first announced the project to set up a vehicle to hold more than 1 billion euros of soured loans one year ago and expectations were that they would launch it by the end of 2014.

Ironing out legal and tax issues, however, took longer than expected, forcing the banks to postpone the plan and take a more gradual step-by-step approach.

"The main legal hurdles have been overcome and the banks will soon put some of the loans in the vehicle," one of the sources said.

>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance
: ECR -16.6%, DRWI -11.1%, CONN -10.1%, (reports February total same store sales fell 5.8% y/y; 60-plus day delinquency rate of 9.2%), PCOM -9.8%, MOMO -7.4%, SMTC -6.1%, ERJ -5%, WTI -4.1%, CCRN -4%, JOY -4%, HRB -3.9%, ALIM -2.1%, ACHN -2.1%, CPE -1.3%, CNQ -1.3%, ALSK -1.2%

M&A news: ABBV -5.1% (to acquire PCYC transaction valued at $261.25 pershare)

Other news: VNDA -6.9% (announces top-line results of the Phase II proof of concept clinical study investigating the safety and efficacy of tradipitant as a monotherapy in the treatment of chronic pruritus in patients with atopic dermatitis), ECA -4.1% (announces agreement with underwriters syndicate, for bought deal purchase of ~85.62 mln common shares of its common stock for C$14.60/share; ~C$1.25 billion in gross proceeds expected ), NSR -4.1% (releases statment on the LNPA Vendor Selection), ARI -3.3% (announces public offering of 10 mln shares of common stock), COMM -2.2% (files for common stock offering by selling shareholders; announces sale of 20 mln shares of common stock an affiliate of the Carlyle Group), CNHI -1.1% (in sympathy with JOY earnings), CAT -0.9% (in sympathy with JOY earnings)

Analyst comments: SALT -3.6% (downgraded to Neutral from Outperform at Credit Suisse), ANF -2% (downgraded to Neutral from Buy at Nomura), QSR -1.9% (downgraded to Neutral from Buy at Goldman), MPEL -1.5% (downgraded to Neutral from Overweight at HSBC Securities), MCD -0.8% (downgraded to Neutral from Overweight at Piper Jaffray), INXN -0.8% (downgraded to Hold from Buy at Canaccord Genuity)

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
: BIOL +27.7%, IFMI +24.2%, XUE +12%, PEIX +10.7%, VSLR +9%, HRTG +8%, MLR +6.9%, AV +5.9%, RNDY +5.7%, CSIQ +5.2%, DAR +3.7%, MNK +3.3%, ALG +2.2%, COST +1.9%, SQNM +1.4%, BKCC +1.4%, TSE +1.3%, AXAS +1.2%, OSIR +1.1%, CIEN +1%, .

M&A news: PCYC +10% (AbbVie (ABBV) to acquire Pharmacyclics; transaction valued at $261.25 pershare), ARWR +8.5% (acquires Novartis' (NVS) RNAi R&D portfolio), INSM +3.9% (Daily Mail discusses takeover speculation in INSM; RHHBY, MRK, AZN are possible suitors), MNK +3.3% (will acquire Ikaria from a Madison Dearborn-led investor group in a transaction valued at ~$2.3 bln), MAC +2% (may be a takeover target by Simon Property Group (SPG), according to WSJ), GDP +1% (light volume but saw late-day gain following reports co could consider going private; downgraded by boutique firm this morning)

Select Bio/pharma related names showing strength: APPY +10.2%, AVEO +8.4%, KYTH +5.6%, ZIOP +5.3%, BIOC +3.8%, ARIA +3.5%, AEZS +3.3%, OREX +2.5%, CLRX +2.4%, CYTX +-3.5%

Select oil/gas related names showing strength: REXX +3.9%, SFY +3.8%, LINE +2.3%, WLT +2.3%, STO +1.3%

Other news: EYES +19% (announces successful first implants of the Argus II Retinal Prosthesis System at two new centers in Italy), TENX +11.6% (highlights two recently-published scientific articles on the potential benefits of its lead candidate, levosimendan, in patients undergoing cardiac surgery), NAVB +9.9% (Navidea Biopharma and Norgine BV affiliate SpePharm AG announce European Commercial Partnership regarding Lymphoseek, also reported earnings), ONCY +8.9% (announced that an oral presentation by the Company's research collaborators in Professor Kevin Harrington's lab at the Institute for Cancer Research), TGTX +7.3% (discloses terms of Global Collaboration with Checkpoint Therapeutics; to make an up-front payment of $500k), CPRX +4% (Amifampridine phosphate for the treatment of congenital myasthenic syndromes granted FDA Orphan Designation status), NBG +3.5% (strong EU mkts today), GLDD +2.9% (awarded ~$134.5 mln Army contract), SFM +1.8% (Sprouts Farmers Market announced the launch of a public offering of 15,847,800 shares of its common stock held by affiliates of Apollo Global Management), .

Analyst comments: CLDN +14.1% (initiated with a Buy at ROTH Capital, tgt $70), GDOT +5.4% (upgraded to Outperform from Neutral at Credit Suisse), DNKN +2.8% (upgraded to Buy from Neutral at Goldman), AEO +2.4% (upgraded to Buy from Neutral at B. Riley & Co; upgraded to Buy from Hold at Stifel), KAR +1.7% (initiated with a Buy at Sun Trust Rbsn Humphrey)

(BFW) ECB Raises ELA Ceiling for Greek Banks by EU500m: Capital.gr


ECB Raises ELA Ceiling for Greek Banks by EU500m: Capital.gr
2015-03-05 10:31:16.955 GMT


By Marcus Bensasson
(Bloomberg) -- The ECB’s governing council increased the
amount of Emergency Liquidity Assistance Greek banks can access
to EU68.8b from EU68.3b, Athens-based news website Capital.gr
reports, without saying how it got the information.
* A Bank of Greece spokesman declined to comment when
contacted by phone
* NOTE: Earlier, Greece Struggles to Make Debt Math Work in
Bailout Standoff


For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>

To contact the reporter on this story:
Marcus Bensasson in Athens at +30-210-741-9077 or
mbensasson@bloomberg.net
To contact the editors responsible for this story:
Fergal O’Brien at +44-20-3525-7152 or
fobrien@bloomberg.net
Nikos Chrysoloras

(BFW) BMW Says It’s Not in Talks With Apple on Car Manufacturing


BMW Says It’s Not in Talks With Apple on Car Manufacturing
2015-03-05 10:22:20.417 GMT


By Elisabeth Behrmann
(Bloomberg) -- Co.’s “regular contacts” with
telecommunications, IT companies, including Apple, limited to
vehicles’ connectivity, BMW spokesman Mathias Schmidt says in e-
mail.
* NOTE: Schmidt responding to Auto Motor & Sport magazine
preview report citing people familiar with the matter that
“intensive talks” between BMW, Apple focus on possible
development of carmaker’s electric i3 model as a vehicle for
smartphone manufacturer


For Related News and Information:
Today’s top stories: TOP <GO>
Top news in Europe: TOPE <GO>

To contact the reporter on this story:
Elisabeth Behrmann in Geneva at +49-89-24447-8801 or
ebehrmann1@bloomberg.net
To contact the editors responsible for this story:
Chris Reiter at +49-30-70010-6226 or
creiter2@bloomberg.net
Tom Lavell, Naomi Kresge